ReacX Pharmaceuticals

ReacX Pharmaceuticals is a private, pre-revenue biotech leveraging its acquired ProNeura® drug delivery platform to develop long-acting implantable therapeutics for chronic conditions. Its lead asset is Probuphine®, an approved but currently withdrawn implant for opioid use disorder (OUD), which the company plans to relaunch. The pipeline also includes a nalmefene implant for OUD relapse prevention and potential programs for chronic pruritus, targeting significant unmet needs in addiction medicine and beyond with its sustained-release technology.

ProNeura®: A proprietary, long-term, continuous drug delivery platform using a solid matrix implant made of ethylene-vinyl acetate (EVA) and drug substance. It is administered subdermally and delivers stable medication levels for up to one year.

ReacX competes in the Medication-Assisted Treatment (MAT) market against other long-acting formulations like Indivior's Sublocade® (buprenorphine injection) and monthly injections of naltrexone (Vivitrol®). Its implantable, year-long duration aims to differentiate on convenience and adherence, but must overcome established competitors and market penetration challenges.